News and Announcements
Income2Wealth Armchair Investor Community Received $2.1M
- Published April 07, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our proactive Development Team continue to deliver stylish contemporary homes via The Mills Master Plan for Tasmanian locals. Meanwhile our Armchair Developer Community continue to enjoy solid and reliable monthly returns into their bank accounts and SMSF’s each and every month.
Following on from last months capital return, the March distribution our Armchair Investor Community received totalled $2,108,767.
That’s a total of just over $37 Million paid in Monthly Distributions to our Investor Community since 2018 and 100% of Due Capital On Completed Investments Returned.
If you’d like to discover more about our Armchair Investment Options, please call Income2Wealth’s office on 1800600890 or email [email protected].
You should consider the information and associated risks in the Disclosure Documents in full before making any kind of investment decision. Investment products offered by I2W are not bank deposits. Past performance is not an indicator of future performance.
About The Company
At Income2Wealth we understand how difficult it can be to tune out the clutter of everyday demands, emotions and the varied opinions that can cloud your investment decisions. It’s easy to become overwhelmed listening to the conflicting investment strategies proposed by your friends, your family and various industry ‘experts’. We want to help you build the confidence and clarity you need to become a successful investor and we don’t leave anything to chance.
We don’t believe in a cookie cutter approach to investing – not every investment pathway is suited to every investor.
At Income2Wealth, our focus is on providing a wide variety of investment pathways aimed at helping you achieve your goals on your budget and in your timeframe.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
